Boston, Mass., October 19, 2016 – The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of emerging therapies for the treatment of atopic dermatitis. The report will include a systematic review of the comparative clinical effectiveness and cost-effectiveness of selected treatments. A preliminary list of treatments to be reviewed will be posted as part of a draft scoping document scheduled to be released on November 7, 2016.
A three-week “Open Input” period begins today, and comments on the topic will be accepted from any and all interested stakeholders. The Open Input period is intended to allow stakeholders to share key information relevant to the development of ICER’s scope and evidence report. During this time, ICER will also contact key patient groups and clinical experts to gain further insights.
For more information about the Open Input period, including a further explanation of the types of information that may be most helpful to development of the report, visit ICER’s website. There are no page limits to Open Input submissions, and input received will be incorporated throughout report development. All input can be emailed to firstname.lastname@example.org and must be received by 5PM CT on November 7, 2016 in order to be considered.
A Draft Scoping Document, which will provide more detail on ICER’s proposed scope for the review, will be available on or about November 7, 2016 and will be open to public comment for three weeks.
The report will be the subject of a May 2017 meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC). During the meeting, the independent Council will deliberate and vote on the comparative clinical effectiveness and value of the treatments included in the review. The Council will discuss the implications of the votes for policy and practice with a roundtable including clinical experts and patients to provide guidance to patients, clinicians, insurers, and policymakers confronted with decisions on how best to treat atopic dermatitis to ensure optimal patient outcomes.
Public Comment on Draft Scope: November 7- November 28, 2016
Final Scoping Document Posted: December 9, 2016
Draft Evidence Report and Draft Voting Questions Posted: March 24, 2017
Public Comment on Draft Evidence Report and Voting Questions: March 24 – April 21, 2017
Evidence Report and Revised Voting Questions Posted: May 5, 2017
Public Meeting of the Midwest CEPAC: May 18, 2017